Three details:
1. Takeda sold the drug to reduce debt, and the deal includes 400 Takeda employees meant to help Novartis sell Xiidra and another eye drug called RTH258 awaiting regulatory approval. Approved by the FDA in 2016, Xiidra had $400 million in sales last year.
2. This marks Takeda’s first divestment since its takeover of Shire in January.
3. Novartis sold its eyecare division, Alcon, in March after moving its prescription eye drugs into Novartis’ pharmaceuticals business.
More articles on supply chain:
EyePoint Pharmaceuticals sees increase in Q1 revenue: 3 details
NextGen Healthcare adds free mobile app for enterprise clients
GPO chooses OptumRx for pharmacy care services: 3 quick details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
